Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

OTHER 11NETWORK 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 14Pancreatic Neoplasms 5Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Non-Small Cell Lung Cancer 2Uterine Cervical Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pan-tumor 1Neoplasm Metastasis 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Klatskin Tumor 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × S 1 (combination) × Clear all
NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡